What should I know first?

Gender identity is a person's experience of their gender. It is different from sexual orientation, which concerns attraction, and from gender expression, which includes presentation and clothing. Gender dysphoria concerns distress, not an identity judged unacceptable by others. Distress may involve physical characteristics, how someone is addressed, or the way others perceive them.

People may be transgender, nonbinary, or use other language for their experience. These identities do not automatically establish a diagnosis. Respectful support should not depend on someone adopting a particular label or seeking a particular medical intervention.

Experiences and impact

Distress may relate to bodily characteristics or being treated as a gender that does not fit the person's experience. Gender diversity itself is not a symptom. People differ in their goals, degree of distress and whether they want any medical intervention.

Assessment and access

Assessment explores the person's experience, distress, health and support needs without requiring a predetermined outcome. In the NHS England information, adults can discuss a specialist referral with their GP. Under-18 pathways involve children's mental health or paediatric services; the referral service identifies nation-specific differences.

How common is it?

Counts of transgender people, gender-service referrals and diagnoses of dysphoria measure different things. Referral numbers also depend on awareness, access, stigma and recording practices. Not everyone with dysphoria seeks specialist care, and people seeking care do not all experience the same distress. Older clinic samples cannot establish a current UK population rate. This article does not give one unsupported percentage for a diverse range of experiences or imply that identity alone defines illness.

What Causes It?

There is no established single cause that explains an individual's gender identity or gender dysphoria. Developmental influences do not justify reducing identity to parenting, trauma or one biological mechanism. Distress also has more than one source. Discomfort with physical characteristics may coexist with rejection, bullying, discrimination or barriers to care.

Addressing social adversity matters even when it does not explain every aspect of dysphoria. Families should not be automatically blamed, and a person's identity should not be treated as a symptom to eliminate.

What Do We Know About the Brain?

Research has examined aspects of brain development and gender-related experience, but these studies do not provide a diagnostic brain scan or a test of someone's identity. Group averages cannot determine what a particular person needs. A person does not have to demonstrate a particular biological explanation to receive respectful care.

Small studies should not be treated as a settled mechanism. Clinical assessment focuses on experience, distress, functioning, goals and informed decision-making rather than classifying a brain as definitively male or female.

Conditions With Similar Symptoms

Body dysmorphic disorder involves preoccupation with perceived appearance defects; it is not the same as distress about gender-related characteristics. Depression, anxiety, trauma-related distress, or broader dissatisfaction with the body may require their own assessment. They can occur alongside dysphoria rather than automatically replacing its explanation.

Sexual orientation and consensual gender expression are not psychiatric diagnoses. Clinicians also distinguish exploration from persistent distress without assuming that every young person's development must follow the same path. Diagnostic care should make room for uncertainty without dismissing or prematurely defining the person's experience.

Other Conditions That Can Occur Together

Anxiety and depression can coexist and deserve appropriate treatment in their own right. Bullying, family conflict, social isolation, and discrimination may add substantially to distress. These difficulties are not evidence that gender diversity itself is pathological. Assessment should include safety when there is hopelessness or self-harm, alongside the person's strengths and supportive relationships.

Practical problems such as school attendance or access to ordinary healthcare also matter. Support for coexisting conditions can begin while someone is waiting for specialist assessment; care should not be reduced to a single gender-related decision.

Treatment and support

Support can include psychological care, practical help and, for adults where appropriate, specialist discussion of medical options. Not everyone wants the same intervention. Coexisting mental health needs can be addressed during a wait; support should not depend on completing a gender-service assessment.

Medical options and changing policy

Adult specialist care may discuss hormones, expected effects, monitoring and fertility implications. Decisions depend on the person's goals, health and informed consent; not everyone seeks medical treatment. This article gives no doses and does not establish individual eligibility. Unregulated online products are not a safe substitute for clinical care.

In England, NHS initiation of masculinising or feminising hormones for under-18s was paused from 9 March 2026 while the policy was reconsidered. The ministerial statement distinguishes new prescriptions from existing NHS treatment for 16- and 17-year-olds, which may continue following individual clinical review and strengthened consent discussions. Psychological and other support remain important.

The consultation closed on 7 June 2026. An official parliamentary briefing updated on 15 October reported that its response was still unpublished and, on information supplied by NHS England, the final policy was expected later that autumn. This is a dated account of a policy still awaiting finalisation, not a claim that a consultation proposal has become a permanent UK-wide ban.

NHS commissioning, private medicine-supply law and the policies of other UK nations are separate questions.

Services across the four UK nations

In England, adults can discuss a specialist gender-service referral with their GP. Children's referrals use the specialist CYP pathway through relevant children's mental health or paediatric services. The national referral support service also covers Welsh referrals, but describes different arrangements for moving towards adult care; an England rule should not automatically be applied to a Welsh patient.

In Wales, the Welsh Gender Service is an adult service, with GP referral and Welsh residency/registration requirements; children's support follows a separate route. Its commissioner announced on 6 October 2026 that surgical referrals, assessments and new surgeries had been paused from 24 August pending independent review. Individual reviews may support reinstatement where appropriate. This is not a statement that all gender care has stopped; the Welsh Gender Service remains the contact for ongoing care.

In Scotland, adult access uses Scottish NHS gender services rather than the England referral system. The Scottish Government's published service evaluation describes Sandyford's young people's service and a clinician-referral route introduced in August 2024. Its Chief Medical Officer's July 2024 letter separately records the Scottish pause on new puberty-suppressing and masculinising/feminising hormone treatment for young people.

These are dated Scottish decisions, not effects automatically imposed by the March 2026 England consultation; the treating Scottish service should confirm its current individual care arrangements.

In Northern Ireland, Belfast Trust identifies Knowing Our Identity for children, young people and families, generally through CAMHS or learning-disability services, and Brackenburn for adult specialist care. A ministerial answer on 3 August 2026 described a planned lifespan service model but no confirmed starting date. It should not be described as already replacing those services. Assessment and support do not themselves promise a particular medicine or immediate treatment.

Puberty suppression: NHS policy and supply law

Puberty-suppressing medicines are distinct from masculinising or feminising hormones. NHS England's March 2024 policy does not make puberty suppression a routine commissioned treatment for children and young people with gender incongruence or dysphoria. That commissioning decision must be distinguished from research approval and from medicine-supply law.

The UK-wide 2024 Order restricting private sales and supplies of specified GnRH analogues took effect on 1 January 2025. It restricts private supply for under-18 gender-related puberty suppression, with defined exceptions and conditions. It does not ban every use of these medicines: authorised trials are outside its prohibition, NHS prescriptions are excepted, and it contains specific provisions for other clinical purposes and limited continuation of pre-existing treatment.

Those exceptions do not create an NHS entitlement or remove separate prescribing responsibilities.

The Order requires a first review by 1 October 2027; this is a review requirement, not an automatic expiry date. Individual lawful supply depends on the exact circumstances and current text. This overview should not be used to obtain, prescribe or change a medicine without the responsible clinician and pharmacist.

Research and evidence under review

On 19 June 2026 the MHRA announced agreement on a modified PATHWAYS trial protocol, with strengthened safety safeguards, alongside ethical approval. Reporting only the February pause would therefore be out of date. Regulatory approval of a study is not proof that its treatment benefits are established, that routine NHS commissioning has changed, or that any particular person can enrol.

Participation and service decisions also have national dimensions. The Northern Ireland minister's 3 August answer described further Executive consideration before revisiting Northern Ireland's participation. Readers should use the current study and service information for recruitment; this article does not promise an open place, a recruitment date or identical participation across all four nations.

What to Expect Over Time

Experiences and support needs can change over time. Some people know clearly what they want; others benefit from more exploration, and no single course should be assumed. Follow-up can assess distress, daily functioning, relationships, and the effects of any chosen intervention.

Improvement should be understood in relation to the person's goals rather than conformity to someone else's expectations. Medical decisions may involve continuing monitoring, while psychological and social support can remain useful regardless of treatment choices. A change in needs is a reason to review the plan, not a failure of identity.

Support while waiting

A GP or existing mental health team can help with distress, anxiety, depression and everyday difficulties while specialist appointments are pending. Ask who is coordinating care, how changes in health should be reported and what support is available locally. Specialist waiting lists do not mean other healthcare must stop.

Young people approaching an age boundary need a transition plan that identifies the receiving service, referral responsibility and support during a gap. England and Wales have different arrangements within the national referral service; Scotland and Northern Ireland use separate services. Family or other trusted support can be useful where the person wants it and it is appropriate to their circumstances.

Urgent support

Immediate danger, serious self-harm or inability to stay safe requires urgent help through local emergency or crisis services. Do not delay care because a specialist gender appointment is pending. The edition selected on this website does not establish which emergency system covers the reader.

History and terminology

Psychiatric terminology moved away from treating gender identity itself as the problem. DSM-5 replaced gender identity disorder with gender dysphoria in 2013, emphasising clinically significant distress. WHO separately moved gender incongruence into ICD-11's sexual-health chapter, outside mental disorders. These are related but non-identical concepts, and an international revision does not demonstrate uniform NHS coding adoption.

Keeping a healthcare classification can support access without classifying transgender identity as a mental illness. Historical search terms need explanation, not uncritical reuse.

Sources and References

  1. What is Gender Dysphoria?

    Scope: International scientific background; not UK prescribing or healthcare guidance.

  2. Gender incongruence and transgender health in the ICD

    Scope: International scientific background; not UK prescribing or healthcare guidance.

  3. Gender dysphoria and incongruence

    Scope: England patient and service information.

  4. Patients and parents — National CYP Gender Referral Support Service

    Scope: England and Wales, with explicitly different referral and transition details.

  5. Updated guidance to primary care about unregulated providers who supply hormone medications to children and young people for gender incongruence

    Scope: England.

  6. Recognizing medical emergencies

    Scope: International explanatory background; not UK prescribing or service guidance.

  7. NHSE policy on masculinising and feminising hormones — HCWS1391

    Scope: England NHS commissioning; not a UK-wide private-prescribing rule.

  8. Hormone treatments and age of consent: Government policy

    Scope: England commissioning-policy status.

  9. Puberty suppressing hormones for children and young people who have gender incongruence / gender dysphoria

    Scope: England NHS commissioning.

  10. The Medicines (Gonadotrophin-Releasing Hormone Analogues) (Restrictions on Private Sales and Supplies) Order 2024

    Scope: United Kingdom.

  11. Update on the PATHWAYS clinical trial

    Scope: UK trial regulation; not uniform NHS service participation.

  12. PATHWAYS trial

    Scope: Trial sponsor information; individual recruitment not established.

  13. Welsh Gender Service — Your referral and appointment

    Scope: Wales.

  14. Details of the independent clinical review of referrals for gender-affirming surgery — 6th October 2026

    Scope: Wales gender surgery pathway.

  15. Accessing adult gender identity healthcare in Scotland

    Scope: Scotland.

  16. Gender identity healthcare: evaluation of the impact of Scottish Government funding — young people's service

    Scope: Scotland.

  17. Cass review: implications for Scotland — letter from Chief Medical Officer Professor Sir Gregor Smith

    Scope: Scotland.

  18. Knowing Our Identity

    Scope: Northern Ireland.

  19. Brackenburn Clinic

    Scope: Northern Ireland.

  20. AQW 40761/22-27 — Gender Identity Service and PATHWAYS trial

    Scope: Northern Ireland.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top